Developer docs
API playgroundTry for free, no card

Search company profiles

Stalicla

Full company profile

uuid0000fk3

Namestring
Stalicla
Legal namestring
STALICLA SA
Websiteurl
stalicla.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGeneva, Switzerland
HQ citystring
Geneva
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision neuro medicine, neurodevelopmental disorder treatments, autism spectrum disorder drugs, substance use disorder therapy, multiomics drug discovery
Industry4 codes
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage precision biopharmaceuticals for neurodevelopmental disorders
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Biopharmaceutical company developing precision medicines for neurodevelopmental disorders. Revenue will be generated through licensing deals, development and commercial milestones, and royalties from drug sales upon regulatory approval.

stalicla.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Stalicla develops precision medicines for neurodevelopmental and neuropsychiatric disorders through its proprietary DEPI platform, which applies AI and multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The pipeline includes three clinical-stage drug candidates: STP1 (ibudilast/bumetanide combination for ASD-Phen1 subgroup), STP2/SFX-01 (stabilized sulforaphane for ASD-Phen2, in-licensed from TheraCryf), and STP7/Mavoglurant (mGluR5 NAM licensed from Novartis for cocaine use disorder and ASD-Phen7).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 1b trials showed STP1 was well-tolerated with dose-dependent target engagement and improvements in executive function and memory
+3 more records
Product overview1 text field

STALICLA's core offering is the DEPI (Databased Endophenotyping Patient Identification) precision neuro medicine platform, which uses AI-driven multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The company's pipeline includes three therapeutic candidates: STP1 (fixed dose combination of ibudilast and bumetanide for ASD-Phenotype 1), STP2 (stabilized sulforaphane for ASD-Phenotype 2), and STP7 (mavoglurant, an mGluR5 NAM for cocaine use disorder and ASD). The company also offers DEPI as a platform for industry partners to de-risk drug development in neurodevelopmental and neuropsychiatric disorders.

Product and service5 records
1DEPI (Databased Endophenotyping Patient Identification) Platform
CategoryAI/ML precision medicine platform
Description

AI-driven precision neuro medicine platform that uses multiomics analysis (genomics, transcriptomics, proteomics, pharmacogenomics), patient data, and machine learning to identify patient subgroups with similar disease signatures and match them with tailored drug treatments for neurodevelopmental and neuropsychiatric disorders.

2STP1
CategoryClinical-stage drug candidate (ASD)
Description

Fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) tailored as a precision medicine treatment candidate for ASD-Phenotype 1 subgroup patients, targeting improvements in executive function and memory. Completed Phase 1b trials with demonstrated safety and dose-dependent target engagement.

3STP2 (SFX-01)
CategoryClinical-stage drug candidate (ASD)
Description

Stabilized synthetic form of sulforaphane (patented composition of sulforaphane and alpha cyclodextrin) developed as a precision medicine treatment candidate for ASD-Phenotype 2 subgroup, in-licensed from TheraCryf (formerly Evgen Pharma).

4STP7 (Mavoglurant)
CategoryClinical-stage drug candidate (SUD and ASD)
Description

Most clinically advanced negative allosteric modulator of glutamate receptor 5 (mGluR5 NAM), licensed from Novartis and being developed for cocaine use disorder (Phase 3 with NIH/NIDA funding) and ASD Phen7 subgroup. Over 1,800 patients administered in Phase 2 trials up to 2 years.

5NGSTroubleFinder
CategoryBioinformatics software tool
Description

Open-source tool for detection and quantification of contamination and kinship across human NGS data, with sample identity verification and cross-sample contamination detection. Written in Python with a custom parallelized pileup engine in C.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Dr. Paulo Fontoura
Strategic tierCoreTypeOthersAnnounced on2024-09-19
Description

Appointed as Chief Scientific and Clinical Development Advisor. Former Global Head of Neuroscience Clinical Development at Roche with 16 years tenure. Brings expertise in CNS drug development and neurodevelopmental disorders.

stalicla.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-03-27
Description

Partnership to validate EEG-based biomarkers using Firefly's FDA-cleared BNA platform in Stalicla's biologically-enriched ASD subgroups. Leverages DEPI platform and BNA technology for Phase 2 trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-08
Description

CRADA agreement covering Phase 3 clinical trial for mavoglurant in cocaine use disorder, enrolling up to 330 patients. NIDA covers trial costs under its own account. NIH-NIDA fully funds Phase 3 development.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-09
Description

Exclusive in-licensing agreement for mavoglurant (STP7) worldwide for substance-use disorders, NDDs, and other indications. Up to $270M in milestones plus royalties. Novartis also took equity stake in Stalicla.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-10-10
Description

In-licensing agreement for SFX-01 (STP2) worldwide for neurodevelopmental disorder indications. STP2 is a patented composition of sulforaphane and alpha cyclodextrin for ASD-Phen2 subgroup.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-07-20
Description

EU-funded project (€22M total funding) for Euro-Global Platform for Mechanism-based Drug Repurposing. Stalicla leads computational drug repositioning work package with €1.7M allocated budget over 6 years.

7Universitat Autònoma de Barcelona / IBB UAB
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-06-09
Description

Collaborative research partnership in biotechnology, genetics and biomedical engineering.

stalicla.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-11
Description

Phase 1b clinical trial site for STP1 with Dr. Craig Erickson as principal investigator. Successfully completed Phase 1b trials demonstrating safety and target engagement.

9Greenwood Genetic Center (GGC)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2018-04-26
Description

Long-term research partnership for ASD clinical trials. GGC provides autism patient cohorts (several hundred patients with documented records). Dr. Walter Kaufmann joins scientific committee; Dr. Luigi Boccuto served as Chief Scientific Officer.

stalicla.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision medicine company focused on CNS and neuropsychiatric disorders using data-driven patient stratification. Directly comparable to Stalicla's DEPI platform approach of matching therapies to defined patient subtypes.

TypeDirect peer
Description

CNS-focused biopharma developing CNS therapeutics for depression, epilepsy, and rare neurodevelopmental disorders. Comparable clinical-stage CNS pipeline strategy and similar small-molecule repurposing model in brain disorders.

TypeDirect peer
Description

Commercial-stage CNS specialty pharma focused on neurological and psychiatric disorders, including autism-related indications (e.g., Rett syndrome via trofinetide partnership). Comparable CNS franchise focus and small-molecule development approach.

TypeDirect peer
Description

Clinical-stage precision neuroscience company targeting CNS disorders including schizophrenia and autism using circuit-based approaches. Comparable emphasis on defined patient populations and CNS pipeline focus.

5Axial Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing gut-brain targeted therapies for autism and Parkinson's disease. Directly comparable focus on biologically-defined ASD subgroups and CNS precision medicine.

TypeEmerging player
Description

Earlier-stage biotech developing CNS therapeutics for autism and other neurodevelopmental disorders. Comparable therapeutic focus area in ASD, though at earlier development stage with different mechanistic approach.

TypeDirect peer
Description

CNS precision medicine biotech that developed xanomeline-trospium for schizophrenia and was acquired by BMS. Comparable CNS precision-medicine approach and clinical-stage development model in neuropsychiatric indications.

TypeBroad incumbent
Description

Global pharma with a large neuroscience franchise including therapies for Fragile X, SMA, Huntington's, and autism-related conditions. Relevant because Dr. Paulo Fontoura (Stalicla's CSO advisor) led Roche's neuroscience clinical development for 16 years, signaling overlapping CNS development priorities.

TypeBroad incumbent
Description

Global pharma that originally developed mavoglurant and out-licensed it to Stalicla for $270M in milestones. Comparable as a major CNS player and the originator of Stalicla's most advanced clinical asset.

TypeDirect peer
Description

Clinical-stage biopharma using AI-driven drug discovery and repurposing for CNS and immuno-oncology indications. Comparable AI-driven approach to CNS drug development and repurposing of existing compounds.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stalicla

Clinical-stage precision biopharmaceuticals for neurodevelopmental disordersstalicla.com

Stalicla firmographics

Firmographics
Name
Stalicla
Legal name
STALICLA SA
Website
https://stalicla.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Stalicla industry classification

Industry
Product category
Clinical-stage precision biopharmaceuticals for neurodevelopmental disorders
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Precision neuro medicine
  • Neurodevelopmental disorder treatments
  • Autism spectrum disorder drugs
  • Substance use disorder therapy
  • Multiomics drug discovery

Where Stalicla is headquartered

Location

Headquarters

HQ city
Geneva
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Stalicla business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Biopharmaceutical company developing precision medicines for neurodevelopmental disorders. Revenue will be generated through licensing deals, development and commercial milestones, and royalties from drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Stalicla product offering

Product offering

Core offering

Stalicla develops precision medicines for neurodevelopmental and neuropsychiatric disorders through its proprietary DEPI platform, which applies AI and multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The pipeline includes three clinical-stage drug candidates: STP1 (ibudilast/bumetanide combination for ASD-Phen1 subgroup), STP2/SFX-01 (stabilized sulforaphane for ASD-Phen2, in-licensed from TheraCryf), and STP7/Mavoglurant (mGluR5 NAM licensed from Novartis for cocaine use disorder and ASD-Phen7).

Product overview

STALICLA's core offering is the DEPI (Databased Endophenotyping Patient Identification) precision neuro medicine platform, which uses AI-driven multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The company's pipeline includes three therapeutic candidates: STP1 (fixed dose combination of ibudilast and bumetanide for ASD-Phenotype 1), STP2 (stabilized sulforaphane for ASD-Phenotype 2), and STP7 (mavoglurant, an mGluR5 NAM for cocaine use disorder and ASD). The company also offers DEPI as a platform for industry partners to de-risk drug development in neurodevelopmental and neuropsychiatric disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • DEPI (Databased Endophenotyping Patient Identification) Platform AI-driven precision neuro medicine platform that uses multiomics analysis (genomics, transcriptomics, proteomics, pharmacogenomics), patient data, and machine learning to identify patient subgroups with similar disease signatures and match them with tailored drug treatments for neurodevelopmental and neuropsychiatric disorders.
  • STP1 Fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) tailored as a precision medicine treatment candidate for ASD-Phenotype 1 subgroup patients, targeting improvements in executive function and memory. Completed Phase 1b trials with demonstrated safety and dose-dependent target engagement.
  • STP2 (SFX-01) Stabilized synthetic form of sulforaphane (patented composition of sulforaphane and alpha cyclodextrin) developed as a precision medicine treatment candidate for ASD-Phenotype 2 subgroup, in-licensed from TheraCryf (formerly Evgen Pharma).
  • STP7 (Mavoglurant) Most clinically advanced negative allosteric modulator of glutamate receptor 5 (mGluR5 NAM), licensed from Novartis and being developed for cocaine use disorder (Phase 3 with NIH/NIDA funding) and ASD Phen7 subgroup. Over 1,800 patients administered in Phase 2 trials up to 2 years.
  • NGSTroubleFinder Open-source tool for detection and quantification of contamination and kinship across human NGS data, with sample identity verification and cross-sample contamination detection. Written in Python with a custom parallelized pileup engine in C.

Quantifiable outcome

  • Phase 1b trials showed STP1 was well-tolerated with dose-dependent target engagement and improvements in executive function and memory
  • +3 more outcomes

Companies that use Stalicla

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Stalicla technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Stalicla partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, strategic and minor.

  • Dr. Paulo FontouracoreOthers · 19 September 2024Appointed as Chief Scientific and Clinical Development Advisor. Former Global Head of Neuroscience Clinical Development at Roche with 16 years tenure. Brings expertise in CNS drug development and neurodevelopmental disorders.
  • Firefly NeurosciencestrategicTechnology or Integration · 27 March 2023Partnership to validate EEG-based biomarkers using Firefly's FDA-cleared BNA platform in Stalicla's biologically-enriched ASD subgroups. Leverages DEPI platform and BNA technology for Phase 2 trials.
  • National Institute on Drug Abuse (NIDA)coreStrategic or Co-development Partner · 8 March 2023CRADA agreement covering Phase 3 clinical trial for mavoglurant in cocaine use disorder, enrolling up to 330 patients. NIDA covers trial costs under its own account. NIH-NIDA fully funds Phase 3 development.
  • NovartiscoreOEM/ Whitelabel/ Licensing Partner · 9 January 2023Exclusive in-licensing agreement for mavoglurant (STP7) worldwide for substance-use disorders, NDDs, and other indications. Up to $270M in milestones plus royalties. Novartis also took equity stake in Stalicla.
  • Evgen Pharma / TheraCryfcoreOEM/ Whitelabel/ Licensing Partner · 10 October 2022In-licensing agreement for SFX-01 (STP2) worldwide for neurodevelopmental disorder indications. STP2 is a patented composition of sulforaphane and alpha cyclodextrin for ASD-Phen2 subgroup.
  • REPO4EU ConsortiumstrategicStrategic or Co-development Partner · 20 July 2022EU-funded project (€22M total funding) for Euro-Global Platform for Mechanism-based Drug Repurposing. Stalicla leads computational drug repositioning work package with €1.7M allocated budget over 6 years.
  • Universitat Autònoma de Barcelona / IBB UABminorStrategic or Co-development Partner · 9 June 2021Collaborative research partnership in biotechnology, genetics and biomedical engineering.
  • Cincinnati Children's HospitalcoreStrategic or Co-development Partner · 11 May 2021Phase 1b clinical trial site for STP1 with Dr. Craig Erickson as principal investigator. Successfully completed Phase 1b trials demonstrating safety and target engagement.
  • Greenwood Genetic Center (GGC)strategicStrategic or Co-development Partner · 26 April 2018Long-term research partnership for ASD clinical trials. GGC provides autism patient cohorts (several hundred patients with documented records). Dr. Walter Kaufmann joins scientific committee; Dr. Luigi Boccuto served as Chief Scientific Officer.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Stalicla competitors and assessment

Company assessment

Direct peers

  • Neumora Therapeutics: Clinical-stage precision medicine company focused on CNS and neuropsychiatric disorders using data-driven patient stratification. Directly comparable to Stalicla's DEPI platform approach of matching therapies to defined patient subtypes.
  • Sage Therapeutics: CNS-focused biopharma developing CNS therapeutics for depression, epilepsy, and rare neurodevelopmental disorders. Comparable clinical-stage CNS pipeline strategy and similar small-molecule repurposing model in brain disorders.
  • Acadia Pharmaceuticals: Commercial-stage CNS specialty pharma focused on neurological and psychiatric disorders, including autism-related indications (e.g., Rett syndrome via trofinetide partnership). Comparable CNS franchise focus and small-molecule development approach.
  • MapLight Therapeutics: Clinical-stage precision neuroscience company targeting CNS disorders including schizophrenia and autism using circuit-based approaches. Comparable emphasis on defined patient populations and CNS pipeline focus.
  • Axial Therapeutics: Clinical-stage biotech developing gut-brain targeted therapies for autism and Parkinson's disease. Directly comparable focus on biologically-defined ASD subgroups and CNS precision medicine.
  • Karuna Therapeutics: CNS precision medicine biotech that developed xanomeline-trospium for schizophrenia and was acquired by BMS. Comparable CNS precision-medicine approach and clinical-stage development model in neuropsychiatric indications.
  • BioXcel Therapeutics: Clinical-stage biopharma using AI-driven drug discovery and repurposing for CNS and immuno-oncology indications. Comparable AI-driven approach to CNS drug development and repurposing of existing compounds.

Emerging players

  • Yamo Pharmaceuticals: Earlier-stage biotech developing CNS therapeutics for autism and other neurodevelopmental disorders. Comparable therapeutic focus area in ASD, though at earlier development stage with different mechanistic approach.

Broad incumbents

  • Roche: Global pharma with a large neuroscience franchise including therapies for Fragile X, SMA, Huntington's, and autism-related conditions. Relevant because Dr. Paulo Fontoura (Stalicla's CSO advisor) led Roche's neuroscience clinical development for 16 years, signaling overlapping CNS development priorities.
  • Novartis: Global pharma that originally developed mavoglurant and out-licensed it to Stalicla for $270M in milestones. Comparable as a major CNS player and the originator of Stalicla's most advanced clinical asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Stalicla social profiles

Digital presence

Stalicla financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stalicla leadership team

Management profile

Number of profiles

Profiles18 records

Stalicla subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Stalicla funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stalicla M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stalicla

What does Stalicla do?

Stalicla develops precision medicines for neurodevelopmental and neuropsychiatric disorders through its proprietary DEPI platform, which applies AI and multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The pipeline includes three clinical-stage drug candidates: STP1 (ibudilast/bumetanide combination for ASD-Phen1 subgroup), STP2/SFX-01 (stabilized sulforaphane for ASD-Phen2, in-licensed from TheraCryf), and STP7/Mavoglurant (mGluR5 NAM licensed from Novartis for cocaine use disorder and ASD-Phen7).

Is Stalicla a public or private company?

Stalicla is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stalicla founded?

Stalicla was founded in 2017. It employs 11 to 50 people.

Where is Stalicla based?

Stalicla is headquartered in Geneva, Switzerland, in the Europe region.

How does Stalicla make money?

One revenue line is on record: licensing and Milestone Payments.

Who are Stalicla's main competitors?

Direct peers on record are Neumora Therapeutics, Sage Therapeutics, Acadia Pharmaceuticals, MapLight Therapeutics, Axial Therapeutics, Karuna Therapeutics and BioXcel Therapeutics. Yamo Pharmaceuticals is listed as an emerging player. Broad incumbents are Roche and Novartis.

Does Stalicla have an API?

No public API is recorded for Stalicla.

What industry is Stalicla in?

Stalicla's product category is Clinical-stage precision biopharmaceuticals for neurodevelopmental disorders. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsideprecisionmedicineFive Startups Surfing the PGx WaveThis article profiles five pharmacogenomics startups—GenXys, Kadance, NeuroKaire, PGxAI, and Stalicla—as investor interest in the sector grows amid projected market expansion from $7.6 billion in 2024 to $12.4 billion by 2030, with AI tools in the space expected to surge at 23.9% annually to $12.6 billion by 2033. The featured startups have collectively raised over $85 million in recent funding rounds and include acquisitions such as Kadance's purchase of Kailos Genetics and partnerships like NeuroKaire's collaboration with NeuroSense Therapeutics for Alzheimer's drug development. Stalicla notably advanced its autism spectrum disorder candidate STP1 to Phase II, while the broader M&A landscape saw Telos PGx acquired by Principle Health Systems and Corriel Life Sciences by InformedDNA.VenturelabStalicla raises CHF 2M for neurodevelopmental drug programsStalicla, a Swiss biotech, raised CHF 2M in financing to support its precision medicine programs for neurodevelopmental disorders. The round, backed by Addex Therapeutics, will sustain operations and advance programs like STP7 (mavoglurant) as the company prepares for Series C financing.startupticker.chAddex Therapeutics leads Stalicla’s CHF 2 million roundStalicla raised CHF 2 million in a financing round led by Addex Therapeutics, with Addex CEO Tim Dyer joining its board as chairman. The funds will support operations and program development as the company prepares for Phase 2 trials of its autism assets STP1 and STP2, and Phase 3 trials of STP7.BioSpaceStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder ProgramsStalicla closed a CHF 2 million financing led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders. The funds will support operations and program development, with STP1 and STP2 assets and STP7 progressing toward Phase 3 trials. The company is preparing for its Series C financing.GlobeNewswireAddex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersAddex Therapeutics led a CHF 2 million investment in Stalicla, a clinical-stage company developing precision medicine for neurodevelopmental and neuropsychiatric disorders. Addex CEO Tim Dyer was appointed to Stalicla's board and nominated as chairman. Stalicla will use the funds to advance its autism-focused drug candidates and support its series C financing.GlobeNewswireStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder ProgramsStalicla closed a CHF 2 million financing led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders. The funds will support operations and program development as the company prepares for its Series C and key partnerships. STP1 and STP2 are advancing toward Phase 2 trials, while STP7 continues Phase 3 development funded by NIH-NIDA.GlobeNewswireAddex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersAddex Therapeutics led a CHF 2 million investment in Stalicla, a clinical-stage company developing precision medicine for neurodevelopmental and neuropsychiatric disorders. Addex CEO Tim Dyer was appointed to Stalicla's board and nominated as chairman. Stalicla will use the funds to advance its autism-focused drug candidates and prepare for Phase 2 trials.AddextherapeuticsAddex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersAddex Therapeutics led a CHF 2 million investment in Stalicla, a clinical-stage company developing precision medicine for neurodevelopmental and neuropsychiatric disorders. Addex CEO Tim Dyer was appointed to Stalicla's board and nominated as chairman. Stalicla will use the funds to advance its autism-focused drug candidates and support its series C financing.PharmiWeb.comStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder ProgramsStalicla closed a CHF 2 million financing led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders. The funds will support operations and program development, with STP1 and STP2 preparing for Phase 2 trials and STP7 progressing toward Phase 3. The company is also preparing for its Series C financing.YahooAddex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersAddex Therapeutics announced it has led a CHF 2 million investment in Stalicla, a Swiss clinical-stage biopharmaceutical company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its autism-focused drug candidates, support asset partnering and its series C financing, with its lead candidate STP1 preparing for Phase 2 trials targeting specific autism subpopulations. As part of the deal, Addex CEO Tim Dyer has been appointed to Stalicla's Board of Directors as Chairman, reinforcing Addex's strategy to support precision therapeutics in CNS disorders while building on its existing 20% equity interest in Neurosterix.